Logo

Roche's Gavreto (pralsetinib) Receives the US FDA's Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

Share this

Roche's Gavreto (pralsetinib) Receives the US FDA's Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

Shots:

  • The approval is based on P-I/II ARROW study involve assessing Gavreto (400mg- qd) n people with rearranged during transfection (RET) fusion-positive NSCLC- RET-mutant MTC- RET fusion-positive thyroid cancer- and other RET-altered solid tumors
  • The study demonstrated durable clinical activity in people with/out prior therapy and regardless of RET alteration genotypes
  • Gavreto is a once-daily- oral precision therapy designed to selectively target RET alterations- including fusions and mutations

­ Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions